Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer

The increased expression of cluster of differentiation (CD)47 has been identified in a number of different tumor types and is recognized as an adverse prognostic factor that indicates an increased risk of mortality in patients. The binding of CD47 to signal regulatory protein α (SIRPα) inhibits the...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-02, Vol.15 (2), p.2017-2023
Main Authors: Zhao, Chun-Lin, Yu, Shuang, Wang, Shu-Hui, Li, Shi-Gang, Wang, Zhi-Ju, Han, Sheng-Na
Format: Article
Language:English
Subjects:
Cancer therapies
Care and treatment
Cellular proteins
Chemotherapy
Development and progression
Esophageal cancer
Esophagus
FDA approval
Gene expression
Genetic aspects
Health aspects
Immunoglobulins
Immunotherapy
Melanoma
Oncology
Patients
Proteins
Radiation therapy
Squamous cell carcinoma
Surgery
Thoracic surgery
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increased expression of cluster of differentiation (CD)47 has been identified in a number of different tumor types and is recognized as an adverse prognostic factor that indicates an increased risk of mortality in patients. The binding of CD47 to signal regulatory protein α (SIRPα) inhibits the macrophage phagocytosis of tumor cells by triggering an inhibitory 'do not eat me' signal. This is one of the mechanisms used by tumor cells to evade immune surveillance. In the present study, CD47 levels and macrophage infiltration were assessed in patients with esophageal squamous cell cancer (ESCC). CD47-overexpressing ESCC cell lines were selected and human M2 macrophage phagocytic activity was measured. The results revealed that CD47 is highly expressed and macrophages are markedly infiltrated in cancerous tissue compared with non-cancerous tissue. High CD47 expression was detected in ESCC cell lines and the results of a phagocytosis assay indicated that human M2 macrophages phagocytized tumor cells in a dose-dependent manner following the blocking of CD47-SIRPα signaling by anti-CD47 antibodies. The results of the present study therefore support the use of anti-CD47 immunotherapy to treat patients with ESCC.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2017.7447